trending Market Intelligence /marketintelligence/en/news-insights/trending/yFHgtUhfNdRErAo_tebUfg2 content esgSubNav
In This List

Vericel's knee repair implant gets US FDA approval

Case Study

Identifying PPE Suppliers During the Pandemic


Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective

Vericel's knee repair implant gets US FDA approval

The U.S. FDA granted approval to Vericel Corp.'s Maci for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients.

Maci is composed of a patient's own cells that are expanded and placed onto a bio-resorbable porcine-derived collagen membrane that is implanted over the area where the defective or damaged tissue was removed.

The safety and efficacy of Maci were shown in a clinical trial designed to demonstrate reduced pain and improved function in comparison to microfracture, an alternative surgical procedure for cartilage repair.